SAN CARLOS, Calif.--(BUSINESS WIRE)--BioCardia®, Inc., a leader in cardiovascular regenerative medicine, today announced receipt of the CE Mark for its Helix 953L Catheter as part of its Helix Transendocardial Delivery System for infusion of biologics to the heart. The new catheter is optimized for larger, dilated hearts, while maintaining compatibility with smaller hearts. It also does not require biotherapeutic programs already using the Helix system for delivery to develop new compatibility data. The Helix 953L catheter will be commercially available in the European Union in the coming months.
Help employers find you! Check out all the jobs and post your resume.
